Demyelinating Disorders

VACCINATION 1 Credit CME Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2 JAMA Neurology

DEMYELINATING DISORDERS 1 Credit CME Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies JAMA Neurology

DEMYELINATING DISORDERS 1 Credit CME Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis JAMA Neurology

VACCINATION 1 Credit CME Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab JAMA Neurology

DEMYELINATING DISORDERS 1 Credit CME Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review JAMA Oncology

DEMYELINATING DISORDERS 1 Credit CME Association of a Marker of N -Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration JAMA Neurology

CLINICAL CHALLENGE 1 Credit CME Sequential Bilateral Vision Loss in a Woman With Scalp Tenderness and Jaw Claudication JAMA Neurology

ETHICS 1 Credit CME A Womanist Approach to Caring for Patients With Empirically Unverifiable Symptoms AMA Journal of Ethics

CORONAVIRUS (COVID-19) 1 Credit CME Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis JAMA Neurology

NEUROLOGY 1 Credit CME Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial JAMA Neurology

DEMYELINATING DISORDERS 1 Credit CME Diagnosis and Treatment of Multiple Sclerosis: A Review JAMA

NEUROLOGY 15m 27s 1 Credit CME Diagnosis and Treatment of Multiple Sclerosis—A Review JAMA

DEMYELINATING DISORDERS 1 Credit CME Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial JAMA Neurology

NEUROLOGY 28m 38s Optic Neuritis Incidence and Prevalence and Association With Systemic and Neurologic Disease JAMA Neurology

CAROTID AND INTRACRANIAL ARTERY DISEASE 1 Credit CME Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related Inflammation JAMA Neurology

CORONAVIRUS (COVID-19) 1 Credit CME Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis JAMA Neurology

NEUROIMAGING 1 Credit CME Hookworm Treatment for Relapsing Multiple Sclerosis: A Randomized Double-Blinded Placebo-Controlled Trial JAMA Neurology

ADVERSE DRUG EVENTS 1 Credit CME Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events JAMA Neurology

DEMYELINATING DISORDERS 1 Credit CME Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses: A Systematic Review and Meta-analysis JAMA Neurology

CNS INFECTIONS 1 Credit CME Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France JAMA Neurology